CN110891575A - 治疗和/或预防光化性角化病的方法 - Google Patents
治疗和/或预防光化性角化病的方法 Download PDFInfo
- Publication number
- CN110891575A CN110891575A CN201880029861.9A CN201880029861A CN110891575A CN 110891575 A CN110891575 A CN 110891575A CN 201880029861 A CN201880029861 A CN 201880029861A CN 110891575 A CN110891575 A CN 110891575A
- Authority
- CN
- China
- Prior art keywords
- days
- subject
- administered
- day
- area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 168
- 208000009621 actinic keratosis Diseases 0.000 title claims abstract description 142
- 238000011282 treatment Methods 0.000 claims description 156
- 230000000694 effects Effects 0.000 claims description 35
- 206010040914 Skin reaction Diseases 0.000 claims description 33
- 210000004761 scalp Anatomy 0.000 claims description 31
- 230000035483 skin reaction Effects 0.000 claims description 28
- 231100000430 skin reaction Toxicity 0.000 claims description 28
- 230000000699 topical effect Effects 0.000 claims description 26
- 230000002411 adverse Effects 0.000 claims description 24
- 230000002354 daily effect Effects 0.000 claims description 24
- 210000000245 forearm Anatomy 0.000 claims description 20
- 230000008961 swelling Effects 0.000 claims description 13
- 230000003810 hyperpigmentation Effects 0.000 claims description 12
- 208000000069 hyperpigmentation Diseases 0.000 claims description 11
- 206010037888 Rash pustular Diseases 0.000 claims description 10
- 208000029561 pustule Diseases 0.000 claims description 10
- 208000003367 Hypopigmentation Diseases 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 208000025865 Ulcer Diseases 0.000 claims description 9
- 230000003628 erosive effect Effects 0.000 claims description 9
- 210000001508 eye Anatomy 0.000 claims description 9
- 210000001061 forehead Anatomy 0.000 claims description 9
- 210000004247 hand Anatomy 0.000 claims description 9
- 230000003425 hypopigmentation Effects 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000036269 ulceration Effects 0.000 claims description 8
- 230000007332 vesicle formation Effects 0.000 claims description 8
- 206010019233 Headaches Diseases 0.000 claims description 7
- 231100000869 headache Toxicity 0.000 claims description 7
- 210000002414 leg Anatomy 0.000 claims description 7
- 210000000088 lip Anatomy 0.000 claims description 7
- 210000005010 torso Anatomy 0.000 claims description 7
- 206010003051 Application site pain Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 210000000617 arm Anatomy 0.000 claims description 6
- 210000005069 ears Anatomy 0.000 claims description 6
- 210000003739 neck Anatomy 0.000 claims description 6
- 210000001331 nose Anatomy 0.000 claims description 6
- 230000003442 weekly effect Effects 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 5
- 210000000744 eyelid Anatomy 0.000 claims description 5
- 210000002683 foot Anatomy 0.000 claims description 5
- 230000007803 itching Effects 0.000 claims description 5
- 201000009240 nasopharyngitis Diseases 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 201000003004 ptosis Diseases 0.000 claims description 5
- 206010049041 Application site infection Diseases 0.000 claims description 3
- 206010003046 Application site irritation Diseases 0.000 claims description 3
- 206010003053 Application site pruritus Diseases 0.000 claims description 3
- 206010053424 Application site swelling Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000007794 irritation Effects 0.000 claims description 3
- 206010006784 Burning sensation Diseases 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 208000023409 throat pain Diseases 0.000 claims 2
- 230000003203 everyday effect Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 description 77
- 239000003814 drug Substances 0.000 description 22
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 18
- 229940107670 picato Drugs 0.000 description 18
- 206010015150 Erythema Diseases 0.000 description 12
- 206010042674 Swelling Diseases 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000037390 scarring Effects 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 239000002131 composite material Substances 0.000 description 8
- 231100000321 erythema Toxicity 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 description 8
- VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 description 7
- VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical compound C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 description 7
- 238000011200 topical administration Methods 0.000 description 7
- 206010004146 Basal cell carcinoma Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000035618 desquamation Effects 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 238000000315 cryotherapy Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002428 photodynamic therapy Methods 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 206010059516 Skin toxicity Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 3
- 229960002751 imiquimod Drugs 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- MCVVUJPXSBQTRZ-ONEGZZNKSA-N methyl (e)-but-2-enoate Chemical compound COC(=O)\C=C\C MCVVUJPXSBQTRZ-ONEGZZNKSA-N 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 231100000438 skin toxicity Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 208000019750 Administration site reaction Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 206010041101 Small intestinal obstruction Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002681 cryosurgery Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001329 hyperkeratotic effect Effects 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000013105 post hoc analysis Methods 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 206010056951 Actinic cheilitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003055 Application site reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 208000011873 mild conjunctivitis Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 231100001099 no skin toxicity Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000000697 oral hormonal contraceptive Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- -1 salt compound Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469889P | 2017-03-10 | 2017-03-10 | |
| US62/469,889 | 2017-03-10 | ||
| PCT/US2018/021929 WO2018165647A1 (en) | 2017-03-10 | 2018-03-12 | Methods of treating and/or preventing actinic keratosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110891575A true CN110891575A (zh) | 2020-03-17 |
Family
ID=63446658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880029861.9A Pending CN110891575A (zh) | 2017-03-10 | 2018-03-12 | 治疗和/或预防光化性角化病的方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10617693B2 (https=) |
| EP (2) | EP3592355B1 (https=) |
| JP (3) | JP7502863B2 (https=) |
| KR (2) | KR20240090837A (https=) |
| CN (1) | CN110891575A (https=) |
| AU (2) | AU2018231144B2 (https=) |
| BR (1) | BR112019018687A2 (https=) |
| CA (1) | CA3055938A1 (https=) |
| DK (1) | DK3592355T3 (https=) |
| ES (1) | ES3060528T3 (https=) |
| FI (1) | FI3592355T3 (https=) |
| HR (1) | HRP20260155T1 (https=) |
| IL (1) | IL269182B2 (https=) |
| LT (1) | LT3592355T (https=) |
| MX (2) | MX387658B (https=) |
| NZ (1) | NZ757105A (https=) |
| PL (1) | PL3592355T3 (https=) |
| PT (1) | PT3592355T (https=) |
| RS (1) | RS67713B1 (https=) |
| TW (1) | TWI841523B (https=) |
| WO (1) | WO2018165647A1 (https=) |
| ZA (1) | ZA202100106B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025077886A1 (zh) * | 2023-10-13 | 2025-04-17 | 恩康药业科技（广州）有限公司 | 治疗和/或预防日光性角化病的化合物及方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968574B2 (en) * | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| WO2018165647A1 (en) * | 2017-03-10 | 2018-09-13 | Athenex, Inc. | Methods of treating and/or preventing actinic keratosis |
| IL326637A (en) | 2017-09-07 | 2026-04-01 | Atnx Spv Llc | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide |
| US11752156B2 (en) * | 2018-03-07 | 2023-09-12 | Athenex HK Innovative Limited | Compositions and methods for treating hyperproliferative skin disorders |
| WO2019188918A1 (ja) * | 2018-03-28 | 2019-10-03 | テルモ株式会社 | 医療デバイスおよび処置用法 |
| US20220305021A1 (en) * | 2019-06-05 | 2022-09-29 | Athenex, Inc. | Methods of treating and/or preventing psoriasis |
| CA3205857A1 (en) * | 2021-01-21 | 2022-07-28 | Michael MOLYNEAUX | Compositions and methods for treatment of skin cancers |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110021555A1 (en) * | 2008-12-19 | 2011-01-27 | Graceway Pharmaceuticals, Llc | Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0519424B8 (pt) | 2004-12-28 | 2021-05-25 | Athenex Inc | compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| EP2041071B1 (en) | 2006-06-29 | 2014-06-18 | Kinex Pharmaceuticals, LLC | Biaryl compositions and methods for modulating a kinase cascade |
| US7538252B2 (en) | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| US7939529B2 (en) | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| TWI457336B (zh) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
| US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
| EP2155681B1 (en) | 2007-05-17 | 2018-05-02 | Athenex, Inc. | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| EP2143421A1 (en) | 2008-07-07 | 2010-01-13 | Almirall Hermal GmbH | Topical composition for the treatment of actinic keratosis |
| US8741857B1 (en) * | 2012-01-30 | 2014-06-03 | Lawrence Moy | Treatments for actinic keratoses |
| NZ606177A (en) * | 2012-01-30 | 2014-03-28 | Dolorgiet Gmbh & Co Kg | Compositions for the treatment of actinic keratosis |
| JP6280546B2 (ja) | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| WO2018165647A1 (en) * | 2017-03-10 | 2018-09-13 | Athenex, Inc. | Methods of treating and/or preventing actinic keratosis |
-
2018
- 2018-03-12 WO PCT/US2018/021929 patent/WO2018165647A1/en not_active Ceased
- 2018-03-12 PL PL18764980.1T patent/PL3592355T3/pl unknown
- 2018-03-12 LT LTEPPCT/US2018/021929T patent/LT3592355T/lt unknown
- 2018-03-12 EP EP18764980.1A patent/EP3592355B1/en active Active
- 2018-03-12 JP JP2019549396A patent/JP7502863B2/ja active Active
- 2018-03-12 MX MX2019010707A patent/MX387658B/es unknown
- 2018-03-12 FI FIEP18764980.1T patent/FI3592355T3/fi active
- 2018-03-12 CN CN201880029861.9A patent/CN110891575A/zh active Pending
- 2018-03-12 HR HRP20260155TT patent/HRP20260155T1/hr unknown
- 2018-03-12 NZ NZ757105A patent/NZ757105A/en unknown
- 2018-03-12 PT PT187649801T patent/PT3592355T/pt unknown
- 2018-03-12 IL IL269182A patent/IL269182B2/en unknown
- 2018-03-12 EP EP25210508.5A patent/EP4659740A3/en active Pending
- 2018-03-12 KR KR1020247017149A patent/KR20240090837A/ko active Pending
- 2018-03-12 DK DK18764980.1T patent/DK3592355T3/da active
- 2018-03-12 RS RS20260134A patent/RS67713B1/sr unknown
- 2018-03-12 ES ES18764980T patent/ES3060528T3/es active Active
- 2018-03-12 US US15/918,100 patent/US10617693B2/en active Active
- 2018-03-12 TW TW107108242A patent/TWI841523B/zh active
- 2018-03-12 AU AU2018231144A patent/AU2018231144B2/en active Active
- 2018-03-12 BR BR112019018687-5A patent/BR112019018687A2/pt not_active Application Discontinuation
- 2018-03-12 KR KR1020197029678A patent/KR20190141661A/ko not_active Ceased
- 2018-03-12 CA CA3055938A patent/CA3055938A1/en active Pending
-
2019
- 2019-09-09 MX MX2021013354A patent/MX2021013354A/es unknown
-
2020
- 2020-02-28 US US16/804,092 patent/US11497750B2/en active Active
-
2021
- 2021-01-07 ZA ZA2021/00106A patent/ZA202100106B/en unknown
-
2022
- 2022-10-11 US US17/963,502 patent/US20230172942A1/en active Pending
- 2022-11-11 JP JP2022180723A patent/JP2023015269A/ja active Pending
-
2024
- 2024-03-20 AU AU2024201828A patent/AU2024201828B2/en active Active
- 2024-11-28 JP JP2024207319A patent/JP2025029010A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110021555A1 (en) * | 2008-12-19 | 2011-01-27 | Graceway Pharmaceuticals, Llc | Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses |
Non-Patent Citations (2)
| Title |
|---|
| KINEX PHARMACEUTICALS: "Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)", 《HTTPS://WWW.PRNEWSWIRE.COM/NEWS- RELEASES/KINEX-PHARMACEUTICALS-ANNOUNCES-ALLOWANCE-OF-THE-INVESTIGATIONAL-NEW-DRUG-IND-APPLICATION-FOR-KX2-391-OINTMENT-BY-THE-UNITED-STATES-FOOD-AND-DRUG-ADMINISTRATION-FDA-268466522.HTML》 * |
| 赵文丽: "FDA 接受 KX2-391 软膏治疗光化性角化病的研究性新药申请", 《国际药学研究杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025077886A1 (zh) * | 2023-10-13 | 2025-04-17 | 恩康药业科技（广州）有限公司 | 治疗和/或预防日光性角化病的化合物及方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024201828B2 (en) | Methods of treating and/or preventing actinic keratosis | |
| CN105792829A (zh) | 使用伊维菌素治疗丘疹脓疱性红斑痤疮 | |
| JP2011510907A (ja) | 尋常性ざ瘡の長期間の処置のためのアダパレンおよび過酸化ベンゾイルの使用 | |
| US9713608B2 (en) | Method for topically treating actinic keratosis on the trunk (except chest) or extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate) | |
| JP3830963B2 (ja) | 乾癬治療 | |
| RU2805929C2 (ru) | Способы лечения и/или предотвращения актинического кератоза | |
| HK40020549A (en) | Kx2‑391/kx‑01 for use in the treatment of actinic keratosis | |
| HK40020549B (en) | Kx2‑391/kx‑01 for use in the treatment of actinic keratosis | |
| BR122025000862A2 (pt) | Usos do composto kx-01 no tratamento e/ou prevenção da ceratose actínica | |
| TW202112379A (zh) | 治療及／或預防乾癬之方法 | |
| Abbas et al. | The role of antimetabolite medication compared with traditional technique (cryotherapy) for treatment of verrucae | |
| TWI418347B (zh) | 治療疱疹病毒感染的方法 | |
| Dermotoi | Therapeutics 45 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Guan Mianfen Inventor after: Liu Yaonan Inventor after: E. D. Kramer Inventor after: D.L. Cutler Inventor after: Fang Rongsheng Inventor before: M-F.R.Guan Inventor before: J.Y-N.Liu Inventor before: E. D. Kramer Inventor before: D.L. Cutler Inventor before: J.Fang |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230413 Address after: New York, United States Applicant after: Anzix Special Purpose Co.,Ltd. Address before: New York, United States Applicant before: Abbott |